Reported data for Health Assessment Questionnaire (HAQ) change from baseline (CFB) and American College of Rheumatology (ACR) 20/50/70 responses at 6 months.
| Trial | N | Mean HAQ CFB (SD) | ACR20 Responses | ACR50 Responses | ACR70 Responses |
|---|---|---|---|---|---|
| Placebo + MTX | |||||
| AIM | 219 | −0.40 (0.59) | 87 | 37 | 14 |
| Kremer 2005, Kremer 2003 | 119 | −0.14 (0.49*) | 42 | 14 | 2 |
| ATTEST | 110 | −0.29 (0.22) | 46 | 22 | 10 |
| ARMADA | 62 | −0.27 (0.57) | 9 | 5 | 3 |
| DE019 | 200 | −0.24 (0.52) | 59 | 19 | 5 |
| RAPID I | 199 | −0.17 (0.56) | 27 | 15 | 6 |
| RAPID II | 127 | −0.14 (0.45) | 11 | 4 | 1 |
| Weinblatt | 30 | −0.40 (0.49*) | 8 | 1 | 0 |
| TEMPO | 228 | −0.63 (1.08*) | 167 | 92 | 34 |
| GO-FORWARD | 133 | −0.13 (0.58) | 37 | 18 | 7 |
| ATTRACT | 88 | −0.19 (0.49*) | 18 | ||
| Abatacept + MTX | |||||
| AIM | 433 | −0.59 (0.62) | 294 | 173 | 86 |
| Kremer 2005, Kremer 2003 | 115 | −0.42 (0.49*) | 69 | 42 | 19 |
| ATTEST | 156 | −0.68 (0.22) | 104 | 63 | 32 |
| Adalimumab + MTX | |||||
| ARMADA | 67 | −0.62 (0.63) | 45 | 37 | 18 |
| DE019 | 207 | −0.56 (0.52) | 131 | 81 | 43 |
| Certolizumab + MTX | |||||
| RAPID I | 393 | −0.58 (0.59) | 231 | 146 | 84 |
| RAPID II | 246 | −0.50 (0.47) | 141 | 80 | 39 |
| Etanercept + MTX | |||||
| Weinblatt 1999 | 59 | −0.70 (0.49*) | 42 | 23 | 9 |
| TEMPO | 231 | −0.89 (1.08*) | 188 | 136 | 82 |
| Golimumab + MTX | |||||
| GO-FORWARD | 89 | −0.47 (0.55) | 53 | 33 | 18 |
| Infliximab + MTX | |||||
| ATTEST | 165 | −0.53 (0.29) | 98 | 61 | 40 |
| ATTRACT | 86 | −0.31 (0.49*) | 42 |
↵* SD was estimated. MTX: methotrexate.